Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Dose/intensity and frequency of pain relief needed (analgesic/rescue medication use) · Adolescents and adults undergoing orthodontic treatment
Vibratory stimulation (vibratory adjuncts) led to lower dose/intensity and frequency of pain relief needed (analgesic/rescue… compared with no vibration or placebo vibration; GRADE not reported.
1 finding from 1 review
RR 0.63 [0.44, 0.92]
2 studies
GRADE not reported
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · Catuama
'Catuama' herbal compound (Spanemberg 2012) contributes to the dietary supplements short-term symptom-relief comparison (insufficient/contradictory); no separate estimate reported.
1 study · 72 participants
GRADE not reported
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether physical barriers (tongue protector + reinforced self-control… changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · lycopene
Lycopene (Cano-Carrillo 2014) contributes to the dietary supplements short-term symptom-relief comparison (12 RCTs, insufficient/contradictory); no separate lycopene symptom-relief estimate reported.
1 study · 50 participants
GRADE not reported
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · topical urea 10%
Topical urea 10% (Alvarenga da Silva 2014) contributes to the topical treatments short-term symptom-relief comparison (insufficient/contradictory); no separate estimate reported.
1 study · 38 participants
GRADE not reported
Adverse events: hypertension · patients with Guillain‐Barré syndrome
Corticosteroid leads to lower adverse events ‐ hypertension compared with control (high certainty).
1 finding from 1 review
Number experiencing hypotensive or other adverse effects · People undergoing managed opioid withdrawal
Alpha2‐adrenergic agonist may leads to higher number experiencing hypotensive or other adverse effects compared with methadone (low certainty).
1 finding from 1 review
Adverse effects ‐ cardiovascular ‐ hypotension · acute psychosis
Droperidol showed no clear difference in adverse effects ‐ cardiovascular ‐ hypotension compared with haloperidol (moderate certainty).
1 finding from 1 review
Adverse effects ‐ cardiovascular ‐ hypotension/desaturation · acute psychosis
Droperidol showed no clear difference in adverse effects ‐ cardiovascular ‐ hypotension/desaturation compared with haloperidol (low certainty).
1 finding from 1 review
Length of critical care stay (hours) · adult cardiac surgical patients
1 finding from 1 review
Length of critical care stay (hours) · adult cardiac surgical patients
1 finding from 1 review
Hypotension · people with Acute Respiratory Distress Syndrome
It is very uncertain whether high‐frequency oscillation changes hypotension compared with conventional ventilation (very low certainty).
1 finding from 1 review
Dizziness or hypotension · dialysis patients with depression
1 finding from 1 review
Intervention not reported
Pain intensity (VAS) short term · patients with chronic mechanical neck pain (pain for more than 90 days)
1 finding from 1 review